This white paper arises out of the Pink Ribbon drugs funding & trials conference, held at the faculty of pharmaceutical medicine on 23 March 2017 (full programme provided on page 13-15). The general theme to emerge from the conference is that the UK would benefit from enhanced communication between:
• Pharma, regulators and NICE to expedite drug and pricing approval;
• Regulators, NICE and hospitals to allow hospitals time to prepare for new drugs, for example through horizon scanning, with transparency on costs, efficacy and safety profile;
• Pharma and trials database creators, for example, Cancer Research UK (CRUK), to ensure information on clinical trials is effectively disseminated to those patients who may wish to take part – for the benefit of the patients themselves, as well as the national health service (NHS) and pharma.